MEDNAX (MD) Tops Q3 EPS by 20c ; Provides Outlook

MEDNAX (NYSE: MD) reported Q3 EPS of $0.67, $0.20 better than the analyst estimate of $0.47. Revenue for the quarter came in at $493 million versus the consensus estimate of $475.88 million.

Updated 2025 Outlook

Pediatrix is raising its full year 2025 outlook for Adjusted EBITDA, as defined above, and now anticipates Adjusted EBITDA will likely be in a range of $270 million to $290 million.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and nine months ended September 30, 2025 and 2024 is provided in the financial tables of this press release.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Capital One beats Q2 EPS by $1.13 as Discover integration gains pace
• Star Equity to acquire Harte Hanks for $5.00 per share